Barclays analyst Jack Meehan maintained a Sell rating on Genomic Health (NASDAQ: GHDX) on August 3 and set a price target of $35. The company’s shares closed on Friday at $54.28, close to its 52-week high of $59.49.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 10.6% and a 66.7% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Quidel Corp, and Icon plc.
The word on The Street in general, suggests a Hold analyst consensus rating for Genomic Health with a $50.08 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $59.49 and a one-year low of $26.54. Currently, Genomic Health has an average volume of 308.4K.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GHDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
